Illustrative

MASH after the first nod: a market built around the bottleneck

The Pharma Letter·May 14

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A market has formed around a bottleneck, with the situation being referred to as "mash" after an initial acknowledgement. The nature and implications of this market and bottleneck are not specified. The circumstances surrounding the bottleneck and the market that has developed around it are the subject of discussion.

Full coverage

Wegovy SC approved in Japan for MASH

The Pharma Letter·Jun 22

CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns

Fierce Pharma·Jan 30

Madrigal Pharmaceuticals

The Pharma Letter·Apr 24

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

Fierce Pharma·Aug 18

Fetching the latest headlines…

MASH after the first nod: a market built around the bottleneck

Full coverage

Wegovy SC approved in Japan for MASH

CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns

Madrigal Pharmaceuticals

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

Intercept, after many setbacks, pulls liver disease drug Ocaliva in US

Madrigal’s Rezdiffra wins first FDA nod in NASH, liver fibrosis

FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval

22 Discontinued Mountain Dew Flavors You Might Never See Again